J Korean Ophthalmol Soc > Volume 51(12); 2010 > Article
Journal of the Korean Ophthalmological Society 2010;51(12):1549-1553.
DOI: https://doi.org/10.3341/jkos.2010.51.12.1549    Published online December 15, 2010.
Corneal Endothelial Change After Intravitreal Bevacizumab Injection.
Soh youn Suh, Jeong hee Lee, Roo Min Jun
Department of Ophthalmology, Ewha Womans University School of Medicine, Seoul, Korea. jrmoph@ewha.ac.kr
유리체강 내 베바시주맙이 각막내피세포에 미치는 영향
서소연ㆍ이정희ㆍ전루민
Department of Ophthalmology, Ewha Womans University School of Medicine, Seoul, Korea
Abstract
PURPOSE
To evaluate the in vivo corneal endothelial changes after intravitreal bevacizumab (Avastin(R); Genentech Inc., San Francisco, California, USA) injection. METHODS: A total of 30 eyes of 28 patients who received intravitreal bevacizumab injections were included in the present study. Before injection and one and three months after injection, specular microscopy was performed to analyze the corneal endothelial cell changes. In order to compare the differences in the changes of corneal endothelial cells, the eyes were divided into two groups, a single injection group and a multiple injection group. RESULTS: The mean endothelial cell count decreased from 2,497.4 +/- 427.8 at baseline to 2,421.2 +/- 430.5 at one month and to 2,362.7 +/- 366.2 at three months after the injection in all patients. However, the change in endothelial cell count was not statistically significant. In addition, the postoperative change in endothelial cell count was more prominent in the multiple injection group than in the single injection group, although the difference was again not significant. No significant changes in preoperative or postoperative coefficients of variation for cell area or hexagonalities were observed in either patient group or within each group. CONCLUSIONS: There was no significant change in corneal endothelial cells after intravitreal bevacizumab injection. In addition, there was no significant difference in the changes in corneal endothelial cells according to the number of bevacizumab injections.
Key Words: Bevacizumab;Cornea;Cytotoxicity;Endothelium;Specular microscopy


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next